BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up Following Strong Earnings

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s stock price gapped up before the market opened on Thursday after the company announced better than expected quarterly earnings. The stock had previously closed at $7.55, but opened at $8.20. BioCryst Pharmaceuticals shares last traded at $7.8050, with a volume of 1,432,490 shares changing hands.

The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.07 by $1.05. The firm had revenue of $163.28 million during the quarter, compared to analyst estimates of $151.32 million. BioCryst Pharmaceuticals had a net margin of 30.16% and a negative return on equity of 69.22%. BioCryst Pharmaceuticals’s revenue was up 209.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.13) EPS.

Key Headlines Impacting BioCryst Pharmaceuticals

Here are the key news stories impacting BioCryst Pharmaceuticals this week:

• Positive Sentiment: Q4 earnings sharply beat expectations — GAAP EPS of $1.12 vs. consensus ~$0.07 and quarter revenue above estimates, signaling much stronger profitability and accelerating top‑line growth; investors likely reacted to the surprise beat. Zacks: Q4 Earnings Beat
• Positive Sentiment: Full‑year 2025 results showed strong ORLADEYO performance (net revenue $601.8M, +38% y/y), supporting ongoing revenue momentum and improving free‑cash expectations. GlobeNewsWire: Full‑Year 2025 Results
• Positive Sentiment: Astria acquisition and accompanying guidance boost BioCryst’s HAE franchise and pipeline positioning, which can drive longer‑term revenue expansion and investor confidence in commercial scale. TipRanks: Astria Acquisition
• Positive Sentiment: Analyst sentiment is constructive — consensus rating described as “Moderate Buy,” which can support further upside as coverage and buy‑side interest increases. American Banking News: Analyst Rating
• Neutral Sentiment: Management’s earnings presentation and call provide detail on profitability drivers and product outlook — useful for due diligence but not an immediate directional surprise. Seeking Alpha: Earnings Presentation
• Neutral Sentiment: Market commentary is debating valuation after the recent rebound — some see upside while others question whether the run is already priced in. Yahoo Finance: Valuation Discussion
• Neutral Sentiment: Reported short‑interest data in feeds appears inconsistent (zeros/NaN) and shouldn’t be relied on; no clear short squeeze signal from the published figures.
• Negative Sentiment: Despite the beats, the company still reported a negative net margin and negative ROE; analysts expect negative FY EPS (~‑0.36), so investors should watch sustainability of profits and future guidance. MarketBeat: Earnings Summary

Wall Street Analyst Weigh In

BCRX has been the subject of a number of recent research reports. Zacks Research downgraded BioCryst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, November 4th. Weiss Ratings reiterated a “sell (e+)” rating on shares of BioCryst Pharmaceuticals in a research note on Monday, December 29th. HC Wainwright raised their price objective on BioCryst Pharmaceuticals from $30.00 to $32.00 and gave the company a “buy” rating in a research note on Monday, December 15th. Barclays reduced their target price on BioCryst Pharmaceuticals from $11.00 to $9.00 and set an “equal weight” rating for the company in a report on Tuesday, November 4th. Finally, Evercore initiated coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They set an “outperform” rating and a $17.00 price target on the stock. Ten analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $19.64.

Insider Buying and Selling at BioCryst Pharmaceuticals

In related news, insider Alane P. Barnes sold 21,773 shares of the business’s stock in a transaction dated Monday, December 22nd. The stock was sold at an average price of $7.65, for a total transaction of $166,563.45. Following the transaction, the insider directly owned 398,751 shares in the company, valued at $3,050,445.15. The trade was a 5.18% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold 183,453 shares of company stock valued at $1,330,965 over the last three months. 5.10% of the stock is currently owned by corporate insiders.

Institutional Trading of BioCryst Pharmaceuticals

Several hedge funds have recently modified their holdings of BCRX. Larson Financial Group LLC boosted its position in shares of BioCryst Pharmaceuticals by 1,188.0% in the 4th quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares during the last quarter. Focus Partners Wealth acquired a new position in shares of BioCryst Pharmaceuticals in the third quarter valued at approximately $77,000. Mirae Asset Global Investments Co. Ltd. increased its position in shares of BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 2,115 shares in the last quarter. Farther Finance Advisors LLC raised its holdings in shares of BioCryst Pharmaceuticals by 326.8% during the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 8,109 shares during the period. Finally, Elevation Point Wealth Partners LLC bought a new stake in BioCryst Pharmaceuticals in the 3rd quarter valued at $81,000. 85.88% of the stock is owned by institutional investors.

BioCryst Pharmaceuticals Stock Performance

The firm’s 50-day moving average is $7.14 and its 200 day moving average is $7.40. The firm has a market capitalization of $1.84 billion, a P/E ratio of 7.29 and a beta of 0.83.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.